Compare LBRX & ALRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRX | ALRS |
|---|---|---|
| Founded | 2015 | 1879 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 715.4M |
| IPO Year | N/A | 2019 |
| Metric | LBRX | ALRS |
|---|---|---|
| Price | $28.75 | $28.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $46.60 | $25.40 |
| AVG Volume (30 Days) | 134.2K | ★ 156.5K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.89 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.42 |
| Revenue Next Year | N/A | $4.68 |
| P/E Ratio | ★ N/A | $32.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $20.26 |
| 52 Week High | $33.47 | $29.33 |
| Indicator | LBRX | ALRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 64.84 |
| Support Level | $22.39 | $23.13 |
| Resistance Level | $33.47 | N/A |
| Average True Range (ATR) | 1.51 | 0.67 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 72.32 | 85.60 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.